|
ATE203515T1
(de)
*
|
1996-03-29 |
2001-08-15 |
Searle & Co |
Meta-substituierte phenylsulphonamidderivate
|
|
GB9805655D0
(en)
|
1998-03-16 |
1998-05-13 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6521626B1
(en)
|
1998-03-24 |
2003-02-18 |
Celltech R&D Limited |
Thiocarboxamide derivatives
|
|
JP4064059B2
(ja)
|
1998-04-09 |
2008-03-19 |
明治製菓株式会社 |
インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体
|
|
GB9814414D0
(en)
|
1998-07-03 |
1998-09-02 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
EP1100506A4
(en)
*
|
1998-07-29 |
2002-06-26 |
Merck & Co Inc |
INTEGRIN RECEPTOR ANTAGONISTS
|
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
EA006294B1
(ru)
|
1998-12-23 |
2005-10-27 |
Дж.Д.Сирл Энд Ко. |
Применение комбинации целекоксиба и гемцитабина в комбинированном способе лечебного воздействия при лечении рака поджелудочной железы
|
|
US6291503B1
(en)
|
1999-01-15 |
2001-09-18 |
Bayer Aktiengesellschaft |
β-phenylalanine derivatives as integrin antagonists
|
|
US6518283B1
(en)
|
1999-05-28 |
2003-02-11 |
Celltech R&D Limited |
Squaric acid derivatives
|
|
WO2001010844A1
(fr)
|
1999-08-05 |
2001-02-15 |
Meiji Seika Kaisha, Ltd. |
DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE
|
|
AU7353300A
(en)
*
|
1999-09-08 |
2001-04-10 |
Guilford Pharmaceuticals Inc. |
Non-peptidic cyclophilin binding compounds and their use
|
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
|
US6534513B1
(en)
|
1999-09-29 |
2003-03-18 |
Celltech R&D Limited |
Phenylalkanoic acid derivatives
|
|
WO2001027082A1
(en)
*
|
1999-10-08 |
2001-04-19 |
Meiji Seika Kaisha, Ltd. |
3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
|
|
US20050059669A1
(en)
*
|
1999-10-08 |
2005-03-17 |
Keiichi Ajito |
M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
|
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
|
US6455539B2
(en)
|
1999-12-23 |
2002-09-24 |
Celltech R&D Limited |
Squaric acid derivates
|
|
RU2240826C2
(ru)
*
|
2000-02-03 |
2004-11-27 |
Эйсай Ко., Лтд. |
Ингибитор экспрессии интегрина
|
|
EP1332132B1
(en)
|
2000-04-17 |
2007-10-10 |
UCB Pharma, S.A. |
Enamine derivatives as cell adhesion molecules
|
|
US6403608B1
(en)
|
2000-05-30 |
2002-06-11 |
Celltech R&D, Ltd. |
3-Substituted isoquinolin-1-yl derivatives
|
|
US6545013B2
(en)
|
2000-05-30 |
2003-04-08 |
Celltech R&D Limited |
2,7-naphthyridine derivatives
|
|
AU2001267753A1
(en)
|
2000-07-07 |
2002-01-21 |
Celltech R And D Limited |
Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
|
|
EP1305291A1
(en)
|
2000-08-02 |
2003-05-02 |
Celltech R&D Limited |
3-substituted isoquinolin-1-yl derivatives
|
|
US6656971B2
(en)
|
2001-01-25 |
2003-12-02 |
Guilford Pharmaceuticals Inc. |
Trisubstituted carbocyclic cyclophilin binding compounds and their use
|
|
ATE412895T1
(de)
*
|
2001-02-21 |
2008-11-15 |
Eisai R&D Man Co Ltd |
Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
|
|
US6710061B2
(en)
*
|
2001-03-09 |
2004-03-23 |
Ortho-Mcneil Pharamceutical, Inc. |
Aminopyrrolidine sulfonamides as serine protease inhibitors
|
|
GB0127615D0
(en)
*
|
2001-07-09 |
2002-01-09 |
Aventis Pharm Prod Inc |
Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
|
|
US8252902B2
(en)
|
2001-10-22 |
2012-08-28 |
The Scripps Research Institute |
Antibody targeting compounds
|
|
AU2002364260A1
(en)
*
|
2001-12-31 |
2003-07-30 |
Bayer Pharmaceuticals Corporation |
Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
|
|
US20040001835A1
(en)
*
|
2002-03-04 |
2004-01-01 |
Medimmune, Inc. |
Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
|
US20050084489A1
(en)
*
|
2002-03-04 |
2005-04-21 |
Wilder Ronald L. |
Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
|
|
AU2004207002A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US9296697B2
(en)
|
2005-08-24 |
2016-03-29 |
Abbott Laboratories |
Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
|
|
WO2007048127A2
(en)
*
|
2005-10-20 |
2007-04-26 |
The Scripps Research Institute |
Fc labeling for immunostaining and immunotargeting
|
|
EP2222636B1
(en)
|
2007-12-21 |
2013-04-10 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
WO2010093706A2
(en)
|
2009-02-10 |
2010-08-19 |
The Scripps Research Institute |
Chemically programmed vaccination
|
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
|
MX2021012690A
(es)
|
2019-04-19 |
2022-01-31 |
Ligand Pharm Inc |
Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
|
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|